Om

Impact Therapeutics, Inc. is a China-based biopharmaceutical company focused on the research, development, and commercialization of precision oncology therapies. The company concentrates on synthetic lethality, a targeted approach that exploits specific genetic vulnerabilities in cancer cells, aiming to deliver highly selective anti-cancer treatments. Impact Therapeutics’ core commercial product, senaparib, is used as a first-line maintenance therapy for ovarian cancer in China. Beyond its marketed therapy, the company manages an extensive pipeline of small-molecule drug candidates, including programs targeting PARP1/2, PARP1, ATR, WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2. These targets are central to DNA damage response and cell-cycle regulation, making them relevant for hard-to-treat tumors. Headquartered in China and founded in 2009, Impact Therapeutics operates within the biotechnology and medical research sector, serving healthcare providers and patients through partnerships, clinical collaborations, and commercialization efforts in oncology.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I IMPACT THERAPEUTICS MED ENDAVU: Køb IMPACT Therapeutics ($7630) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i IMPACT Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.